The latest developments in insulin injection devices.
The next several years promise dramatic changes in the treatment of diabetes, many of which will be driven by rapidly developing technology. Today's patient with diabetes has ready access to more information about the disease and its treatment options. As a result of this increased knowledge base, insulin-treated patients have become more autonomous in the management of their diabetes and may be better prepared to participate in making informed choices regarding insulin delivery devices. As with any insulin regimen, diabetes educators are encouraged to provide ongoing patient education and follow-up to assure optimal use of these new technologies.
Robertson
K E
KE
Eli Lilly and Company, Indianapolis, Indiana, USA.
Glazer
N B
NB
Eli Lilly and Company, Indianapolis, Indiana, USA.
Campbell
R K
RK
College of Pharmacy, Washington State University, Box 646510, Pullman, WA
D004867:Equipment Design; D004868:Equipment Failure; D005544:Forecasting; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007260:Infusion Pumps / Q000600:supply & distribution*; D007277:Injections, Jet / Q000295:instrumentation*; D007279:Injections, Subcutaneous / Q000295:instrumentation*; D007328:Insulin / Q000008:administration & dosage*; D013594:Syringes / Q000600:supply & distribution*; D014481:United States
D007004:Hypoglycemic Agents; D007328:Insulin